Remove companies cymabay-therapeutics-inc
article thumbnail

CymaBay Investor Sues For Books On $4.3B Gilead Merger

Law 360 M&A

A shareholder of liver disease-focused biopharmaceutical company CymaBay Therapeutics Inc. sued the company in Delaware Chancery Court to extract more information over a proposed $4.3 billion merger with Gilead Sciences Inc.,

52
article thumbnail

Gilead Buying Liver Disease Drugmaker CymaBay For $4.3B

Law 360 M&A

Gilead Sciences Inc. said Monday that it has agreed to purchase liver disease-focused clinical-stage biopharmaceutical company CymaBay Therapeutics Inc. billion in cash.

52
article thumbnail

CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst

Benzinga

Monday, Gilead Sciences Inc (NASDAQ: GILD ) agreed to acquire CymaBay Therapeutics Inc (NASDAQ: CBAY ) for $32.50 The addition of CymaBay’s investigational lead product candidate, seladelpar for primary biliary cholangitis (PBC), including pruritus, complements Gilead’s existing liver portfolio.

Equity 52